Exchange: NASDAQ·Updated 07:40 PM EST

LENZ Earnings

Latest Earnings Results: Q3 '26

Reported: Oct 28

Estimated EPS

-$0.89

Reported EPS

-$0.99

Surprise

-10.84%

Estimated Rev

$4.2M

Reported Rev

$3.38M

Surprise

-19.44%

• Reported GAAP EPS of -$0.99 down -67.80% YoY • Reported revenue of $3.38M down -72.96% YoY • LENZ Therapeutics expects the reorganization to reduce projected 2027 annualized operating expenses by more than 50%, targeting approximately $70M to $75M, excluding stock-based compensation.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Investor Presentation10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
-$0.75
--
--
N/A
Q3 '26
-$0.89
-$0.99
-10.84%
MISSED
Q2 '26
-$1.05
-$1.02
2.90%
BEAT
Q1 '26
-$1.05
-$1.32
-25.99%
MISSED
Q4 '25
-$0.91
-$1.16
-27.71%
MISSED

Advertisement|Remove ads.